Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

Inclusion criteria

• Male or female patient aged of at least 18 years on day of signing informed consent
• Patient with histologically-confirmed diagnosis of Acute Myeloblactic Leukaemia according to classification ELN 2022 (European Leukemia Net 2022)
• Patient who has to initiate treatment venetoclax-azacitidine as first line. Note : triple associations with targeted therapy are not authorized
• Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed.
• Patient must be affiliated or benificiary of a social security system.

Exclusion criteria

• Patient with acute promyelocytic leukemia (APL, AML3)
• Patient with AML eligible to intensive chemotherapy
• Patient previously treaed with venetoclax and/or azacitidine
• Patient participating to another clinical trial with a medicinal product
• Any condition that contraindicates blood sampling procedures required by the protocol
• Any psychological, family, geographical, or social situation that, according to investigator's judgment, could potentially prevent the signing of an informed consent form and/or woulld likely interfere compliance with study procedures.
• Patient under curatorship, guardianship or judicial protection
• Pregnant or breast-feeding female patient.